A Novel Serum Marker, Total Prostate Secretory Protein of 94 Amino Acids, Improves Prostate Cancer Detection and Helps Identify High Grade Cancers at Diagnosis

No AccessJournal of UrologyAdult urology1 Apr 2006A Novel Serum Marker, Total Prostate Secretory Protein of 94 Amino Acids, Improves Prostate Cancer Detection and Helps Identify High Grade Cancers at Diagnosisis accompanied byProstate Specific Antigen and Other Markers for Prostate Cancer Robert K. Nam, Jonathan R. Reeves, Ants Toi, Helene Dulude, John Trachtenberg, Marjan Emami, Luc Daigneault, Chandra Panchal, Linda Sugar, Michael A.S. Jewett, and Steven A. Narod Robert K. NamRobert K. Nam Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada , Jonathan R. ReevesJonathan R. Reeves Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada , Ants ToiAnts Toi Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada , Helene DuludeHelene Dulude Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada , John TrachtenbergJohn Trachtenberg Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada , Marjan EmamiMarjan Emami Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada , Luc DaigneaultLuc Daigneault Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada , Chandra PanchalChandra Panchal Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada , Linda SugarLinda Sugar Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada , Michael A.S. JewettMichael A.S. Jewett Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada , and Steven A. NarodSteven A. Narod Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)00695-6AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: New biomarkers for prostate cancer are needed. We determined whether a novel serum marker, total PSP94 can be used to accomplish these goals. Materials and Methods: We conducted a case-control study of 1,212 men with no previous history of prostate cancer and who underwent a prostate biopsy from 1998 to 2000 because of an increased PSA or an abnormal DRE. Serum PSP94 levels were assessed using a sandwich enzyme-linked immunosorbent assay technique. Cases were patients with prostate cancer, and controls were patients who had no evidence of cancer. Multivariate logistic regression analysis was used to determine whether or not PSP94 levels improved the predictive value for prostate cancer. Results: Of the 1,212 men 596 (49.2%) had cancer detected. The median PSP94 level was significantly lower among cases (2.60 ng/ml) than among controls (3.40 ng/ml, p <0.0001). The adjusted odds ratios for the presence of prostate cancer for patients with the lowest quartile of PSP94, compared to patients in the highest quartile was 2.70 (95% CI 1.8 - 4.0, p <0.0001). Among a subgroup of 649 men in whom PSA had a low predictive value (PSA less than 20 ng/ml, normal DRE and less than 70 years), 260 (40.1%) were found to have cancer. In this subgroup total PSP94 levels helped discriminate between patients with high grade disease (Gleason score 8 or more, median 1.90 ng/ml), moderate grade disease (Gleason score 7, median 2.34 ng/ml) and low grade disease (Gleason score 6 or less, median 2.60 ng/ml, p = 0.007). PSA and the FTPSA were not able to distinguish between patients with different grades in this group. Conclusions: Patients with low total PSP94 levels had a high probability for having prostate cancer detected at biopsy. The total PSP94 level was able to help identify patients with high grade disease among a subset of patients in whom PSA and FTPSA are least informative. References 1 : American Cancer Society guidelines for the early detection of prostate cancer: update, June 10, 1997. Cancer1997; 80: 1805. Google Scholar 2 : Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med1987; 317: 909. Google Scholar 3 : Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med2004; 350: 2239. Google Scholar 4 : The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol2004; 172: 1297. Link, Google Scholar 5 : Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol2003; 170: 1787. Link, Google Scholar 6 : Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol2004; 171: 2239. Link, Google Scholar 7 : Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection. J Clin Oncol2003; 21: 2312. Google Scholar 8 : Identification, purification and characterization of a novel human blood protein with binding affinity for prostate secretory protein of 94 amino acids. Biochem J2005; 385: 105. Google Scholar 9 : Serum bound forms of PSP94 (prostate secretory protein of 94 amino acids) in prostate cancer patients. J Cell Biochem1999; 76: 71. Google Scholar 10 : Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. Prostate1999; 38: 118. Google Scholar 11 : Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res2003; 63: 2072. Google Scholar 12 : Decreased expression of prostatic secretory protein PSP94 in prostate cancer. Cancer Lett1993; 74: 91. Google Scholar 13 : Human prostatic inhibin suppresses tumor growth and inhibits clonogenic cell survival of a model prostatic adenocarcinoma, the Dunning R3327G rat tumor. Cancer Res1993; 53: 4855. Google Scholar 14 : Age and racial distribution of prosatic intraepithelial neoplasia. Eur Urol1996; 30: 138. Google Scholar 15 : Expression study of three secretory proteins (prostatic secretory protein of 94 amino acids, probasin, and seminal vesicle secretion II) in dysplastic and neoplastic rat prostates. Prostate2003; 56: 81. Google Scholar 16 : Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma. Prostate1993; 23: 201. Google Scholar 17 : Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate1988; 12: 39. Google Scholar 18 : Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev1998; 17: 383. Google Scholar 19 : Detection of prostatic-inhibin-like peptide in the cytoplasm of LNCaP cells, a human prostatic adenocarcinoma cell line. Prostate1994; 24: 285. Google Scholar 20 : A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines. Cancer Lett1993; 70: 159. Google Scholar © 2006 by American Urological AssociationFiguresReferencesRelatedDetailsRelated articlesJournal of Urology9 Nov 2018Prostate Specific Antigen and Other Markers for Prostate Cancer Volume 175Issue 4April 2006Page: 1291-1297 Advertisement Copyright & Permissions© 2006 by American Urological AssociationKeywordsprostatic neoplasmsbiopsybiological markersMetricsAuthor Information Robert K. Nam Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada More articles by this author Jonathan R. Reeves Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada More articles by this author Ants Toi Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada More articles by this author Helene Dulude Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada More articles by this author John Trachtenberg Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada More articles by this author Marjan Emami Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada More articles by this author Luc Daigneault Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada More articles by this author Chandra Panchal Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada More articles by this author Linda Sugar Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada More articles by this author Michael A.S. Jewett Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada More articles by this author Steven A. Narod Division of Urology, Sunnybrook and Women's College Health Sciences Centre and University Health Network, Toronto, Ontario Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario Department of Medical Imaging, University Health Network, Toronto, Ontario Department of Public Health Sciences, University of Toronto, Toronto, Ontario Procyon BioPharma Incorporated, Montreal, Quebec, Canada More articles by this author Expand All Advertisement PDF downloadLoading ...